Literature DB >> 2511177

T-cell phenotype is associated with decreased survival in non-Hodgkin's lymphoma.

K Shimizu1, N Hamajima, K Ohnishi, K Hara, A Kunii.   

Abstract

This study was undertaken to determine which if any pretreatment factors are statistically significant determinants of the clinical outcome in patients with non-Hodgkin's lymphoma. The pretreatment factors in 20 patients with T-cell lymphoma, including two patients with adult T-cell leukemia/lymphoma (ATLL), and 28 patients with B-cell lymphoma were evaluated. In a stepwise logistic regression analysis, a T-cell phenotype in addition to high grade histology and pleural involvement demonstrated a statistically significant correlation with decreased response rate, when the analysis did not include patients with ATLL. Analysis by means of the Cox proportional hazards model disclosed that the T-cell phenotype retained a statistically significant correlation with survival after adjustments for other prognostic factors, whether the study included the patients with ATLL or not. The decreased response rate and survival of Japanese patients with non-Hodgkin's lymphoma in comparison with those reported in Western countries seem to be due to increased intrusion of T-cell lymphomas. To permit a reliable comparison of reports on new chemotherapeutic regimens from different institutions, the tumor phenotype must be determined in the population studied.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2511177      PMCID: PMC5917827          DOI: 10.1111/j.1349-7006.1989.tb01704.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  18 in total

1.  Chemotherapy for large-cell lymphoma: optimism and caution.

Authors:  M Coleman
Journal:  Ann Intern Med       Date:  1985-07       Impact factor: 25.391

2.  Weekly CHOP for the treatment of advanced intermediate and high-grade non-Hodgkin's lymphoma.

Authors:  K Shimizu; K Hara; A Kunii
Journal:  Am J Clin Oncol       Date:  1989-06       Impact factor: 2.339

3.  Non-Hodgkin's lymphoma following Hodgkin's disease. A case report and immunohistochemical corroboration.

Authors:  K Shimizu; K Hara; A Kunii
Journal:  Am J Clin Pathol       Date:  1986-09       Impact factor: 2.493

4.  Peripheral T-cell lymphoma: a clinicopathologic study of 42 cases.

Authors:  J P Greer; J C York; J B Cousar; R T Mitchell; J M Flexner; R D Collins; R S Stein
Journal:  J Clin Oncol       Date:  1984-07       Impact factor: 44.544

5.  Lymphoproliferative diseases in Japan and Western countries: Proceedings of the United States--Japan Seminar, September 6 and 7, 1982, in Seattle, Washington.

Authors:  M E Kadin; C W Berard; K Nanba; H Wakasa
Journal:  Hum Pathol       Date:  1983-09       Impact factor: 3.466

6.  MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.

Authors:  P Klimo; J M Connors
Journal:  Ann Intern Med       Date:  1985-05       Impact factor: 25.391

7.  Clinical and phenotypic diversity of T cell lymphomas.

Authors:  S J Horning; L M Weiss; G S Crabtree; R A Warnke
Journal:  Blood       Date:  1986-06       Impact factor: 22.113

8.  Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.

Authors:  R I Fisher; V T DeVita; S M Hubbard; D L Longo; R Wesley; B A Chabner; R C Young
Journal:  Ann Intern Med       Date:  1983-03       Impact factor: 25.391

9.  Some problems on the histopathological diagnosis of non-Hodgkin's malignant lymphoma -- a proposal of a new type.

Authors:  T Suchi; K Tajima; K Nanba; H Wakasa; A Mikata; M Kikuchi; S Mori; S Watanabe; N Mohri; M Shamoto; K Harigaya; T Itagaki; M Matsuda; Y Kirino; K Takagi; S Fukunaga
Journal:  Acta Pathol Jpn       Date:  1979-09

10.  Immunoblastic sarcoma of T-cell versus B-cell origin: I. Clinical features.

Authors:  A M Levine; C R Taylor; D R Schneider; S C Koehler; S J Forman; A Lichtenstein; R J Lukes; D I Feinstein
Journal:  Blood       Date:  1981-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.